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Coleus forskohlii Briq. has been used traditionally for the treatment of several ailments since antiquity in
Ayurveda. In the present study, an approach has been made to evaluate the effect of C. forskohlii and its
major constituents on cytochrome P450 (CYP3A, CYP2B, and CYP2C) mRNA expression in rat hepato-
cytes. To gain better understanding of the herbedrug interaction potential of the chemical constituents
present in C. forskohlii, the extract was subjected to column chromatography followed by standardization
with respect to forskolin, 1-deoxyforskolin, and 1,9-dideoxyforskolin using reversed-phase high-per-
formance liquid chromatography (RP-HPLC). Hepatocytes were treated with extracts, fractions, and
phytoconstituents, followed by extraction and puriﬁcation of total mRNA. Study of mRNA expression was
carried out through reverse transcription polymerase chain reaction, followed by agarose gel electro-
phoresis. Results revealed that the test substances did not show any signiﬁcant mRNA expression
compared to the control against CYP3A, CYP2B, and CYP2C. Positive controls such as dexamethasone and
rifampin showed signiﬁcantly high (p < 0.001) induction potential compared to the control. It can be
concluded that C. forskohlii and its major constituents may not be involved in CYP450 induction-based
drug interaction.
Copyright © 2014, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Coleus forskohlii Briq. (family: Lamiaceae) has a very long history
of use in many traditional herbal medicines, with special reference
to Ayurveda. It is considered to possess antianaphylactic, antiobe-
sity, amebicidal, gastroprotective, bronchodilating, antiaging, anti-
oxidant, anti-inﬂammatory, and anticancer activities. It is being
used exclusively for weight management and hypotension.1e3
Forskolin (1), 1-deoxyforskolin (2), and 1,9-dideoxyforskolin (3)
are structurally related bioactive diterpenoids from C. forskohlii
(Fig. 1). Compound 1 is exclusively known as a fat burner,
commonly used for the treatment of obesity, hypothyroidism, al-
lergies, asthma, eczema, psoriasis, and glaucoma.4 C. forskohlii isnt Centre, Olive Lifesciences
strial Area, Anthrasanahalli,
it).
for Food and Biomolecules,
molecules, National Taiwan Univeone of the commercially important herbal ingredients for weight
loss dietary supplements in the global market.5 Its favorable effects
on body fat management have been well established.6,7
Herbedrug interaction is important for assessing the safety of
the use of herbal products. Most interactions are pharmacokinetic,
and a major concern would be its effect on drug metabolism
through interfering with CYP450.8 More than 50% of clinically used
drugs are metabolized by CYP4503A (CYP3A). CYP4502B (CYP2B) is
capable of metabolizing 25e30% of substrates metabolized by
CYP3A4, whereas CYP4502C (CYP2C) metabolizes 20% of the mar-
keted drugs.9e11 Induction of CYP450 leads to increases in the rate
of metabolite production and hepatic biotransformation of coad-
ministered drugs, and decreases in serum half-life and drug
response.9 There is now increasing literature reference to the ac-
tions of isolated bioactive constituents, and fractions or standard-
ized whole plant extracts on the regulation of CYP450.12,13 In the
present study, commercial extracts and fractions of C. forskohlii
were standardized by reversed-phase high-performance liquid
chromatography (RP-HPLC) based on compounds 1, 2, and 3. The
quantity of compound 1, 2, and 3 in the extracts and fractions werersity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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Fig. 1. Structure of forskolin (1), 1-deoxyforskolin (2), and 1,9-dideoxyforskolin (3).
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constituents on CYP3A, CYP2B, and CYP2C mRNA expression were
evaluated in primary cultures of rat hepatocytes.
2. Materials and methods
2.1. Materials
HPLC-grade anhydrous potassium dihydrogen orthophosphate
(KH2PO4), dipotassium hydrogen phosphate (K2HPO4), orthophos-
phoric acid (H3PO4), water, sodium carbonate (Na2CO3), analytical-
grade dimethyl sulfoxide (DMSO) propanol, silica gel (60e120
mesh), and silica gel 60 F254 plates were procured from E. Merck
Ltd. (Mumbai, India). Membrane ﬁlters (0.45 mm) were obtained
from Millipore (Billerica, MA, USA). Standard 1 (assay 98%), 2
(assay 98%), 3 (assay 97%), 3-(4,5edimethylthiazol-2-yl)-5-
diphenyl tetrazolium bromide, fetal bovine serum, phosphate
buffered saline, Dulbecco's modiﬁed Eagle’s mediumdhigh
glucose, Ham's F-10 medium, and trypsin were purchased from
Sigma-Aldrich Co. (St Louis, MO, USA). EDTA, glucose, penicillin,
and streptomycin were obtained from Hi-Media Laboratories Ltd,
(Mumbai, India). Nuclease-free water, dithiothreitol, RiboLock
RNAse inhibitor, deoxynucleotide mix, oligo dT, and Revert
Aid reverse transcriptase were procured from Thermo Scientiﬁc
(Waltham, MA, USA). Tri reagent from G Biosciences (St. Louis, MO,
USA) was used for the study.
2.2. Plant material
Three different batches of dried C. forskohlii roots were pur-
chased from a regular vendor (Olive Lifesciences Pvt. Ltd., Banga-
lore, Karnataka, India). Voucher specimens were deposited (VU/H/
BD/07/14a, VU/H/BD/07/14b, and VU/H/BD/07/14c) at the Depart-
ment of Botany and Forestry, Vidyasagar University, Midnapore,
West Bengal, India.
2.3. Extraction and fractionation
Roots (2.5 kg) were chopped and extracted with hot ethanol to
produce reddish brown oleoresin (batch no. PM13038). The extract
yield was 9.14% (W/W). This ethanol extract (CEE) was subjected to
column chromatography (60e120 mesh silica) to obtain four
different fractions [12.5%, 20%, and 50% ethyl acetate fraction (EAF)
and 100% methanol fraction (MEF)]. Column chromatography was
started with hexane, followed by ethyl acetate and methanol.
Fractions were collected and combined based on the thin layer
chromatography (TLC) proﬁle. Another two batches (batch
numbers PM13039 and PM13040) of extracts [yield: 8.77% (W/W)
and 9.68% (W/W), respectively] were subjected to column chro-
matography. Ten percent standardized commercial C. forskohlii rootextract (CCF) (batch no. OL130769) was prepared at the production
unit of Olive Lifesciences Pvt. Ltd., and followed the standard
operating procedure (SOP no. MMR-21044).
2.4. RP-HPLC analysis of extracts and fractions
The RP-HPLC system (Shimadzu, Kyoto, Japan) consisted of two
LC-20AP controller pumps; an SPD-M20A PDA detector; and a SIL-
10AP autosampler with a 20-mL loop and integrated LC solution
software. A Phenomenex ODS2 (Phenomenex, Hyderabad, Andhra
Pradesh, India) (250  4.6 mm2; 5 mm) column (USA) was used for
the stationary phase. Separation was achieved using a gradient
elution program for pump A (0.136 g of KH2PO4 and 0.5 mL of
H3PO4 in 1000 mL water) and pump B (acetonitrile) for 50 mi-
nutes, with a ﬂow rate of 1.5 mL/min. Ideal resolution of chro-
matogram was achieved at 205 nm. Test samples were ﬁltered
through a Whatman NYL 0.45 mm syringe ﬁlter (Millipore) prior to
injection. The amount of the phytoconstituents present in the
respective extracts and fractions were determined from the cali-
bration curve.
2.5. Cytotoxicity study
Cytotoxicity of the test samples was assessed based on the
method described by Denizot and Lang.14 The monolayer culture
was incubated with test solution in Dulbecco's modiﬁed Eagle’s
medium (high-glucose medium) at 37C for 3 days in a 5% CO2
atmosphere.
2.6. Isolation of rat hepatocytes
Hepatocytes were isolated from male SpragueeDawley rats
using the modiﬁed collagenase digestion method, as described by
LeCluyse et al.15
2.7. Treatment of hepatocytes
Hepatocytes were washed and treated with commercial ex-
tracts, fractions, and bioactive constituents within nontoxic doses
(100 mg/mL) for 24 hours in Ham's F-10 medium. Cultures were
processed for total RNA extraction. Dexamethasone was used as a
positive inducer of CYP3A and CYP2B.15,16 Rifampin was used as a
positive control against CYP2C.17
2.8. Extraction and puriﬁcation of total mRNA
Total mRNA was extracted from treated hepatocytes using Tri
reagent, according to the protocol described by the manufacturer.
The mRNA pellet was dissolved in nuclease-free water. Purity of
Table 1
RP-HPLC quantiﬁcation of forskolin (1), 1-deoxyforskolin (2), and 1, 9-
dideoxyforskolin (3) in extracts and fractions.
Sample % of 1 (W/W) % of 2 (W/W) % of 3 (W/W)
CCF 11.03 ± 1.41 0.21 ± 0.04 4.60 ± 0.28
CEE 10.00 ± 0.81 1.09 ± 0.05 10.33 ± 1.08
12.5% EAF 0.00 ± 0.00 4.57 ± 0.20 16.35 ± 2.17
20% EAF 34.68 ± 1.46 18.45 ± 1.93 0.00 ± 0.00
Values are represented as mean ± SEM (n ¼ 3).
CCF¼ 10% standardized commercial C. forskohlii extract; CEE¼ C. forskohlii ethanolic
extract; EAF ¼ ethyl acetate fraction; RP-HPLC ¼ reversed-phase high-performance
liquid chromatography; SEM ¼ standard error of mean.
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ples were frozen at 80C for further analysis.
2.9. Reverse transcription polymerase chain reaction
From the total RNA isolated from treated hepatocytes, cDNAs
were prepared. The reaction mixture consisted of 1 cDNA syn-
thesis buffer, dithiothreitol (0.5M), RiboLock RNAse inhibitor (20 U),
deoxynucleotide mix (1.6mM), oligo dT (100 ng), reverse tran-
scriptase (25 U), and total RNA. Primers for CYP3A and CYP2B were
selected as per the method of Park et al.18 Primers for CYP2C and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were
selected following the method of Wauthier et al19 and using the
Gene runner software, ver. 3.05 (Hasting Software Inc., Hasting, NY,
USA; Euroﬁns Bangalore, Karnataka, India), respectively.19 The for-
ward primers for CYP3A, CYP2B, CYP2C, and GAPDH were 50
CCACCAAACCCATGCATACC 30, 50 AGCCGGGGTGTCTTCTATCT 30, 50
TGCCCCCTTTTTACGAGGCT 30, and 50 GTGAAGGTCGGTGTGAACGG
30, respectively. Reverse primers were 50 CAGTATCATGCTGCGGCTTC
30, 50 CAAAGTGGGCTTTTGCTCAT30, 50GGAACAGATGACTCTGAATTCT
30, and 50 CACGCCACAGCTTTCCAGAG 30 for CYP3A, CYP2B, CYP2C,
and GAPDH, respectively. Polymerase chain reaction (MJ mini
thermocycler; Bio Rad, Hercules, CA, USA) conditions were initial
denaturation at 94C for 5minutes, followed by 30 cycles consistingFig. 3. Fold induction of (A) CYP3A, (B) CYP2B, and (C) CYP2C mRNA by RIF, 1, 2, 3, CCF, 12.5
was carried out, followed by Dunnett's multiple comparison test (p < 0.001 and above). ANOV
extract; CEE ¼ C. forskohlii ethanolic extract; DEX ¼ dexamethasone; EAF ¼ ethyl acetate fr
3 ¼ 1,9-dideoxyforskolin.
Fig. 2. Relative (A) CYP3A, (B) CYP2B, and (C) CYP2C mRNA expressions by CC, RIF, 1, 2, 3
commercial C. forskohlii extract; CEE ¼ C. forskohlii ethanolic extract; DEX ¼ dexamethasone
2 ¼ 1-deoxyforskolin; 3 ¼ 1,9-dideoxyforskolin.of denaturation at 94C for 30 seconds, annealing of primers at 62C
for 30 seconds, extension at 72C for 30 seconds, and ﬁnal extension
at 72C for 2 minutes.
2.10. Analysis of ampliﬁed sequences
The ampliﬁed samples were analyzed through 1.8% agarose gel
electrophoresis. The gel was scanned with UV illumination using
digital imaging (Alpha Digi DOC, Upland, CA, USA). Relative sample
expression levels were calculated using Alpha View, version 3.3.1.0.
(Cell Biosciences Inc., Santa Clara, CA, USA).
2.11. Statistical analysis
Experimental data were expressed as the mean ± standard de-
viation or standard error of mean. The results were subjected to
one-way analysis of variance, followed by Dunnett's multiple-
comparison test by ﬁxing the signiﬁcance level at p < 0.05,
p < 0.01 and p < 0.001. The statistical analyses were performed
using GraphPad Prism Version 5.0 (GraphPad Software, Inc., La Jolla,
CA, USA).
3. Results and discussion
Interactions of drugs with herbal preparations or foodstuffs
present unique challenges due to the involvement of a number of
unidentiﬁed chemical entities. Therefore, standardization parame-
ters and marker proﬁling are highly important tools in maintaining
batch-to-batch reproducibility of herbal drugs.20e22 C. forskohlii
extracts were subjected to column chromatography. Different
fractions were collected, and ﬁnally four fractions were selected for
a CYP450 induction study based on the TLC proﬁle. Compounds 1, 2,
and 3 in extracts and fractions were identiﬁed by comparing with
the respective retention times of reference standards. Calibration
curves showed good linearity in the concentration range of
100e800 mg/mL for compounds 1 and 3. In the case of standard 2,% EAF, 20% EAF, 50% EAF, and MEF; mean ± standard deviation; n ¼ 3. One-way ANOVA
A ¼ analysis of variance; CC ¼ control; CCF ¼ 10% standardized commercial C. forskohlii
action; MEF ¼ methanol fraction; RIF ¼ rifampin; 1 ¼ forskolin; 2 ¼ 1-deoxyforskolin;
, CCF, 12.5% EAF, 20% EAF, 50% EAF, and MEF. CC ¼ control; CCF ¼ 10% standardized
; EAF ¼ ethyl acetate fraction; MEF ¼ methanol fraction; RIF ¼ rifampin; 1 ¼ forskolin;
Table 2
Cytotoxicity assay of phytoconstituents, extracts, and fractions.
Sample CTC50 value (mg/mL)
1 >1000 ± 0.93
2 >1000 ± 0.80
3 >1000 ± 0.67
CCF 346.66 ± 0.52
CEE 200.66 ± 0.73
12.5% EAF 215.49 ± 1.22
20% EAF 295.46 ± 1.30
50% EAF 360.93 ± 1.91
MEF 480.10 ± 4.37
Values are represented as mean ± SD (n ¼ 3).
CTC50 ¼ 50% cytotoxic concentration; CCF ¼ 10% standardized
commercial C. forskohlii extract; CEE ¼ C. forskohlii ethanolic
extract; EAF¼ ethyl acetate fraction; MEF¼methanol fraction;
SD ¼ standard deviation; 1 ¼ forskolin; 2 ¼ 1-deoxyforskolin;
3 ¼ 1,9-dideoxyforskolin.
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pounds 1, 2, and 3 in CCF, CEE, and EAF are given in Table 1. The
maximumquantity of compounds 1 and 2was found in 20%EAF. The
maximumyield of compound 3was observed in 12.5% EAF (Table 1).
In 50% EAF and MEF, the quantity of compounds 1, 2, and 3 was 0.
Relative mRNA expressions of CYP3A, CYP2B, and CYP2C by
C. forskohlii extracts, fractions, and phytoconstituents on agarose gel
are represented in Figs. 2A, 2B, and 2C, respectively. Values are
depicted as arbitrary units normalized to (GAPDH) mRNA. The in-
duction effects of extracts, fractions, and phytoconstituents on
CYP3A, CYP2B, and CYP2C are shown in Figs. 3A, 3B, and 3C,
respectively. Based on cytotoxicity results (Table 2), the test dose
(100mg/mL)was conﬁrmed formRNAexpression study. Extracts and
fractions did not show any signiﬁcant expression of CYP3A, CYP2B,
and CYP2CmRNA compared to the control. Positive controls such as
dexamethasone (10mM) and rifampin (50mM) showed signiﬁcant
fold induction (p < 0.001) compared to the control. Results revealed
that none of the studied phytoconstituents was involved in CYP3A,
CYP2B, and CYP2C mRNA induction. CCF; CEE; 12.5%, 20%, and 50%
EAF; andMEF did not showany signiﬁcantmRNAexpression against
CYP3A, CYP2B, and CYP2C, compared to positive inducers.
Induction of CYP450 is of maximum concern during drug
development due to their potential role in the metabolism of drugs.
ThemRNA expression assay is awidely accepted and reliable tool for
determining the induction potential of test substances.23 If a drug
produces a change in thecatalytic activityormRNAexpression that is
>40% of that of the positive control, then it is considered an effective
inducer. Moreover, the Food and Drug Administration (FDA) has
validated the CYP450 induction study and recommended that in-
duction value of the positive control should be twofold times greater
than the blank.24 Yokotani et al25 reported that Coleus extract
showed induction potential against CYP2C in vivo, as well as inhi-
bition potential against CYP2C in vitro. In both in vivo and in vitro
assays, the effect ofmainbioactive compound1wasnegligible. In the
present in vitro assay, C. forskohlii extracts, fractions, and compounds
1, 2, and 3 did not show any signiﬁcant CYP3A, CYP2B, and CYP2C
induction potential compared to positive controls. Fold induction
values of positive controls were two times more compared to the
control, which conﬁrmed the assay precision. The detail mecha-
nisms of induction are not within the scope of the present study.
4. Conclusion
Based on the study results, it can be concluded that C. forskohlii
and its major bioactive constituents may not be involved in CYP450
mRNA expression-based drug interaction, and safe to consume.
Further studies using human hepatic mRNA and clinical trials are
need.Conﬂicts of interest
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